Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307975 | 0.81 | EPHX2 (0.54) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL1157557 | 0.79 | EPHX2 (0.55) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL1157555 | 0.77 | EPHX2 (0.53) | EPHX2KMT2ACASP3CHRM3MDM4 | |
| SCHEMBL9171875 | 0.76 | EPHX2 (0.52) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL1001375 | 0.76 | EPHX2 (0.60) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL29679600 | 0.76 | EPHX2 (0.60) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL8366872 | 0.76 | EPHX2 (0.75) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL29913938 | 0.75 | EPHX2 (0.60) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL119223 | 0.75 | EPHX2 (0.60) | EPHX2KMT2ACASP3FABP7FABP5 | |
| SCHEMBL29401765 | 0.75 | EPHX2 (0.60) | EPHX2KMT2ACASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150190466-A1 | METHODS OF TREATING METABOLIC DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-09 | — | — | US | disclosed |
| US-20130160150-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-06-20 | — | — | US | disclosed |
| US-8460880-B2 | Compositions, splice variants and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-7678889-B2 | Compositions and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090263411-A1 | Compositions, splice variants and methods relating to ovarian specific genes and proteins | DIAZYME LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009076651-A9 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009076651-A2 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090118175-A1 | Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer | MACINA ROBERTO A | 2009-05-07 | — | — | US | disclosed |
| US-20080260761-A1 | Compositions, Splice Variants and Methods Relating to Cancer Specific Genes and Proteins | DIADEXUS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2002040672-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040720-A2 | COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040535-A2 | COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002038810-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002039431-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038606-A2 | COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002036807-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036808-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |